Antipsychotics induce insulin resistance without weight gain

July 18, 2013
Antipsychotics induce insulin resistance without weight gain
Atypical antipsychotic drugs induce insulin resistance even in the absence of weight gain and mechanisms regulating eating behavior, according to a study published online July 8 in Diabetes.

(HealthDay)—Atypical antipsychotic drugs induce insulin resistance even in the absence of weight gain and mechanisms regulating eating behavior, according to a study published online July 8 in Diabetes.

To examine whether have detrimental metabolic effects independent of weight gain or , Karen L. Teff, Ph.D., from the Monell Chemical Senses Center in Philadelphia, and colleagues treated healthy people as inpatients in a controlled setting with olanzapine, , or placebo for nine days (10 people per group) while maintaining activity levels.

The researchers found that, compared with placebo, olanzapine (which has been strongly associated with weight gain) treatment was associated with significant increases in postprandial insulin, glucagon-like peptide 1, and glucagon, as well as insulin resistance. In contrast, aripiprazole (which has been considered metabolically sparing) had no effect on postprandial hormones but also induced . The changes occurred without weight gain, increase in food intake and hunger, or psychiatric disease.

"Our findings suggest that interventions inhibiting weight gain in atypical antipsychotic-treated patients may be only partially effective in preventing metabolic disease since the drugs are exerting direct effects on tissue function," Teff and colleagues conclude.

Explore further: The metabolic effects of antipsychotic drugs

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

The metabolic effects of antipsychotic drugs

July 12, 2011

Research to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, may explain why some antipsychotic ...

Calorie-restricted weight loss restores ghrelin sensitivity

January 21, 2013

(HealthDay)—In a mouse model, calorie-restricted weight loss reverses the high-fat diet-induced ghrelin resistance that may contribute to rebound weight gain, according to research published online Jan. 10 in Endocrinology.

Use of adjunctive antipsychotic medications in depression

March 12, 2013

A study published this week in PLOS Medicine finds that while antipsychotic medications are associated with small-to-moderate improvements in depressive symptoms in adults, there is little evidence for improvement on measures ...

Intensive glycemic control linked to highest weight gains

March 21, 2013

(HealthDay)—Weight gain is higher in patients with type 2 diabetes mellitus (T2DM) who receive more intensive glycemic control treatment and is associated with a reduction of A1C from baseline, according to research published ...

Recommended for you

Which diabetes drug is best?

July 19, 2016

(HealthDay)—No single drug to treat type 2 diabetes stands out from the pack when it comes to reducing the risks of heart disease, stroke or premature death, a new research review finds.

Gut bacteria imbalance increases diabetes risk

July 13, 2016

Currently, scientists think the major contributors to insulin resistance are excess weight and physical inactivity, yet ground-breaking new research by an EU funded European-Chinese team of investigators called MetaHit have ...

Team explores genetic architecture of type 2 diabetes

July 11, 2016

New research from a large international team of scientists offers a more complete picture of the genes responsible for type 2 diabetes, demonstrating that previously identified common alleles shared by many in the world are ...

Normal weight may not protect against diabetes

July 14, 2016

(HealthDay)—Type 2 diabetes has long been considered a disease of the overweight and obese, but a new study challenges that notion. It finds nearly one in five normal-weight people has prediabetes—a condition that can ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

DanielHaszard
not rated yet Jul 19, 2013
Remember the Zyprexa scandal.

Zyprexa (Olanzapine) Diabetes connection conflict of interest.
Eli Lilly made $70 billion to date,paid $1.4 billion in criminal fines.
Thousands got diabetes as Zyprexa side effect and have to take Lilly insulin to treat the diabetes that was caused by their Zyprexa.
Eli Lilly Zyprexa can ruin your Pancreas and make you a type 2 diabetic in just a few months of use.I took it 1996-2000 and now am a diabetic for it.

The Eli Lilly company made an astounding $70 BILLION on Zyprexa that they PUSHED on the elderly and underage children (*Viva Zyprexa* Lilly sales rep slogan) with wanton disregard for the side effects
*FIVE at FIVE*
The Zyprexa antipsychotic drug,whose side effects can include weight gain and diabetes, was sold to Veterans,children in foster care, elderly in nursing homes.
*Five at Five* was the Zyprexa sales rep slogan, meaning *5mg dispensed at 5pm would keep patients quiet*.
*Tell the truth don't be afraid*-- Daniel Haszard
http://www.zyprexa-victims.com

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.